Page 39 - டெக்சாஸ் தொழில்நுட்பம் பல்கலைக்கழகம் ஆரோக்கியம் அறிவியல் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டெக்சாஸ் தொழில்நுட்பம் பல்கலைக்கழகம் ஆரோக்கியம் அறிவியல் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டெக்சாஸ் தொழில்நுட்பம் பல்கலைக்கழகம் ஆரோக்கியம் அறிவியல் மையம் Today - Breaking & Trending Today

City, health officials tout decrease in number of active COVID-19 cases

'Toci' and COVID; Exercise for Arthritic Knees; It's TTHealthWatch!


Rick Lange: Do people with COVID benefit from a blood thinner?
Elizabeth: A really exhaustive look so far at the human gut microbiome and how it may be related to disease.
Rick: And a different anti-inflammatory medication for people with COVID and respiratory problems.
Elizabeth: That s what we re talking about this week on TT HealthWatch, your weekly look at the medical headlines from Texas Tech University Health Sciences Center in El Paso. I m Elizabeth Tracey, a Baltimore-based medical journalist.
Rick: And I m Rick Lange, president of the Texas Tech University Health Sciences Center in El Paso, where I m also the dean of the Paul L. Foster School of Medicine. ....

United States , United Kingdom , El Paso , Rick Lange , Elizabeth Tracey , Gut Microbiome Modulates The Protective Association , Uva Health System , Texas Tech University Health Sciences Center , Paull Foster School Of Medicine , Johns Hopkins Medicine , Im Elizabeth Tracey , Im Rick Lange , British Medical , Personalized Responses , Dietary Composition Trial , Gut Microbiome Modulates , Protective Association , Mediterranean Diet , Cardiometabolic Disease Risk , Im Elizabeth , Him Rick , Bacterial Infectious Disease , Disorder Of Lung , Disorder Of Respiratory System , Co Vid , ஒன்றுபட்டது மாநிலங்களில் ,

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon


February 18, 2021
Despite having no significant safety concerns, an advisory panel to the US Food and Drug Administration said yesterday that it could not find enough evidence of efficacy and benefit to recommend premarket approval (PMA) of a below-the-knee drug-coated balloon (DCB) for the treatment of PAD.
After a full day of discussion, the Circulatory Devices Panel of the Medical Devices Advisory Committee
voted 15-2 (with one member abstaining) that reasonable assurance of safety was demonstrated for the DCB, made by Lutonix, a subsidiary of Becton, Dickinson and Company (BD).
On the question of reasonable assurance of efficacy, however, the vote was the same 15-2 (with one member abstaining) that efficacy was not demonstrated. Similarly, on the question of whether the panel believed that the benefits outweighed the risks, the vote was 14-3 (with one member abstaining) that they did not. ....

United States , University Of Pennsylvania , El Paso , John Hirshfeld , Bernard Gersh , Edwin Gravereaux , Joaquine Cigarroa , Michael Miller , Richard Lange , Haraldur Bjarnason , Md Mayo Clinical College Of Medicine , Md Texas Tech University Health Sciences Center , Do Miller Care Group , Md University Of Pennsylvania School Medicine , Drug Administration , Md Oregon Health Science University , Circulatory Devices Panel , Medical Devices Advisory Committeevoted , Major Deficiency Letter , Not Approvable , Texas Tech University Health Sciences Center , Oregon Health , Science University , New Technologies , Mayo Clinical College , Miller Care Group ,